TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05978037

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1 and/or RH5.2-VLP with Matrix-M
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1 and/or RH5.2-VLP with Matrix-M
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1 and/or RH5.2-VLP with Matrix-M
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial.
Study: NCT05865977

Intervention type: DEVICE
Intervention: diaphragmatic tissue Doppler imaging，dTDI
Description: dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.

Intervention type: DEVICE
Intervention: diaphragmatic tissue Doppler imaging，dTDI
Description: dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
Study: NCT06151782

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat gluten 1000 mg
Description: Nothing to add here

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley gluten 1000 mg
Description: Nothing to add here
Study: NCT05978037

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1 and/or RH5.2-VLP with Matrix-M
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1 and/or RH5.2-VLP with Matrix-M
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial.
Study: NCT06151782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley gluten 50 mg
Description: Nothing to add here

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley hydrolyzed gluten 50 mg
Description: Nothing to add here
Study: NCT05990842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: the individual will receive 1 dose of antibiotic during anesthetic induction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the individual will receive 10 ml of saline during anesthetic induction
Study: NCT05919368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yam pill
Description: It consists of sweet potato, white art and ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yam pill
Description: It consists of sweet potato, white art and ginseng
Study: NCT04432675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethl starch
Description: 10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: 10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
Study: NCT04718129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Mindful Awareness Program (YMAP)
Description: The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
Study: NCT06227637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Muscle Vibration compared to Muscle energy technique in SIJD
Description: Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Muscle Vibration compared to Muscle energy technique in SIJD
Description: Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
Study: NCT06450730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy: face-to-face + app
Description: This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos).
Study: NCT05752006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated trunk flexion
Description: A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated trunk flexion
Description: A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
Study: NCT05064930

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Bifidobacterium lactis
Description: The probiotic will be administered orally over a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Bacillus coagulans
Description: The probiotic will be administered orally over a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
Study: NCT05706480

Intervention type: DIAGNOSTIC_TEST
Intervention: colored periodontal probes (CPP)
Description: The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded

Intervention type: DIAGNOSTIC_TEST
Intervention: standard periodontal probes (SPP)
Description: The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded

Intervention type: DIAGNOSTIC_TEST
Intervention: transgingival sounding with an endodontic file
Description: the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
Study: NCT05173324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
Study: NCT06274658

Intervention type: BEHAVIORAL
Intervention: High-intensity interval exercise
Description: Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.

Intervention type: BEHAVIORAL
Intervention: High-intensity interval exercise
Description: Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
Study: NCT05799118

Intervention type: GENETIC
Intervention: GWAS
Description: The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
Study: NCT05758324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri PNEA
Description: 4 sequences of 10 tablets (one intake)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 sequences of 10 tablets (one intake)
Study: NCT05250830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueRelief device
Description: TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TrueRelief device
Description: The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
Study: NCT04263948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picado system internet platform and connected objects
Description: The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
Study: NCT06482580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF exercise
Description: Ankle and foot exercises practiced for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clam exercise
Description: Hip exercise practiced for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-foot exercise
Description: Foot exercise practiced together for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-foot exercise
Description: Foot exercise practiced together for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-foot exercise
Description: Foot exercise practiced together for 6 weeks.
Study: NCT06243822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
Study: NCT06070740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
Description: Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators.
Study: NCT04914741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100mg orally on Days 1-5 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100mg orally on Days 1-5 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT05429229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VisuXL®
Description: It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lagricel PF®
Description: It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humylub PF®
Description: It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
Study: NCT04633057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ101
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NordiFlex
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
Study: NCT05294211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M•care™ System
Description: The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiotocography (CTG)
Description: A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
Study: NCT06216938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vusolimogene oderparepvec (RP1)
Description: Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
Study: NCT06206278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
Study: NCT05398419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening intervention
Description: Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-musical sounds listening intervention
Description: Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
Study: NCT04622085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANIMERS Chiara LA
Description: 20mg/SciVision Biotech Inc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JUVÉDERM VOLUMA®
Description: 20mg/Allergan, Inc.
Study: NCT05251454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Stimulation
Description: Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
Study: NCT05864183

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile
Description: lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile
Description: lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: CBC will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: CBC will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: Alb/cr ratio
Description: Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: Alb/cr ratio
Description: Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine .
Description: serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine .
Description: serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications

Intervention type: DIAGNOSTIC_TEST
Intervention: CRP
Description: CRP will be measured for all patients to minimize the risk of developing diabetes or its complications